Esperion Therapeutics Inc [NASDAQ: ESPR] stock went on an upward path that rose over 15.00% on Wednesday, amounting to a one-week price increase of more than 13.86%.
Over the last 12 months, ESPR stock dropped by -47.73%. The one-year Esperion Therapeutics Inc stock forecast points to a potential upside of 80.14. The average equity rating for ESPR stock is currently 1.88, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $227.93 million, with 196.66 million shares outstanding and 194.62 million shares in the current float. Compared to the average trading volume of 5.13M shares, ESPR stock reached a trading volume of 5733647 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Esperion Therapeutics Inc [ESPR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ESPR shares is $5.79 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ESPR stock is a recommendation set at 1.88. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Esperion Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 18, 2024. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on December 17, 2024, representing the official price target for Esperion Therapeutics Inc stock. Previously, the target price had yet another raise to $2.50, while BofA Securities analysts kept a Underperform rating on ESPR stock.
ESPR Stock Performance Analysis:
Esperion Therapeutics Inc [ESPR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.86. With this latest performance, ESPR shares gained by 25.19% in over the last four-week period, additionally sinking by -49.56% over the last 6 months – not to mention a drop of -47.73% in the past year of trading.
Insight into Esperion Therapeutics Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Esperion Therapeutics Inc [ESPR] shares currently have an operating margin of -15.40% and a Gross Margin at 65.29%. Esperion Therapeutics Inc’s Net Margin is presently recorded at -59.03%.
Return on Equity for this stock declined to -43.96%, with Return on Assets sitting at -43.96%.
Esperion Therapeutics Inc [ESPR] Institutonal Ownership Details
The top three institutional holders of ESPR stocks are: WASATCH ADVISORS LP with ownership of 16.86 million shares, which is approximately 8.9319%. BLACKROCK INC., holding 13.98 million shares of the stock with an approximate value of $$31.04 million in ESPR stocks shares; and BLACKROCK INC., currently with $$24.01 million in ESPR stock with ownership which is approximately 5.7294%.
